Munich-based patent law expert Dr. Julia Traumann of Pinsent Masons, who previously attended the Munich Local Division’s preliminary injunction hearing in September, said: "It appears that the Court of Appeal shares the Munich Local Division's view on the threshold, even though when reading the decisions carefully, there is a small difference.”
“The Court of Appeal states that a sufficiently certain conviction is lacking, if the court considers it predominantly probable that the patent is invalid, whereby the Munich Local Division had stated that such conviction requires that the validity of the patent in suit is more likely than the invalidity. In any case, the Court of Appeal implicitly confirms the Munich Local Division's rejection of the defendants' argument that, according to German national case law, the revocation of the patent does not have to be predominantly probable, but only possible. With this, the UPC is really developing its own case law that is relevant in the scope of application of the UPC Agreement and the Rules of Procedure," she said.
Sarah Taylor, patent law expert at Pinsent Masons, added: "This decision will provide at least some temporary relief to NanoString, despite the UPC declining to stay the proceedings even though NanoString recently filed for Chapter 11 bankruptcy in the US. There is also an injunction still in place in Germany in favour of 10x Genomics and the oral hearings in the main UPC proceedings for both EP ‘782 and another of 10x Genomics’ patents, EP ‘928, are expected to take place later this year, so the outcome of the dispute between the parties is still far from certain.”